27 September 2017
Reporter: Barney Dixon

Amgen sues Mylan over Neulasta

Amgen has sued Mylan at the US District Court for the Western District of Pennsylvania over patents relating to its Neulasta (pegfilgrastim) chemotherapy support drug.

In February, the US Food and Drug Administration (FDA) accepted Mylan’s abbreviated Biologics License Application (aBLA) for the Neulasta biosimilar for review, but the FDA is yet to approve the application.

In its complaint, Amgen explained that approval of the biosimilar and Mylan’s potential importation and sale of its product would be “infringing”.

Both Amgen and Mylan started exchanging information in March this year under the so-called ‘patent dance’ procedure of the Biologics Price Competition and Innovation Act (BPCIA).

However, Amgen suggested that Mylan failed to provide certain information and “materially prejudiced and impeded Amgen’s ability to review the Mylan aBLA”.

Amgen alleged that Mylan “failed to provide other information that describes the process or processes used to manufacture the biological product that is the subject of’ the Mylan aBLA”.

In June, Amgen took to the US Supreme Court to challenge a US Court of Appeals for the Federal Circuit decision that said the patent dance procedures were completely optional and that a biosimilar applicant can decide to withhold a copy of its biosimilar application.

Amgen said the patent dance was part of the BPCIA’s trade-off and balanced the rights of reference products against those of biosimilar applicants.

The case was sent back to the court of appeals to for a further ruling.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Businesses should prepare for UPC, despite uncertainty
17 October 2017 | London | Reporter: Barney Dixon
Businesses should make preparations for the Unified Patent Court and unitary patent, despite mounting uncertainty surrounding when, if at all, the court will come into effect
Patent ‘irrationality’ causes a negative image of patents
16 October 2017 | London | Reporter: Barney Dixon
Spectators are far more accepting of copyright and trademarks than they are of patents because of “irrationality”, according to Sir Robin Jacob
Partner promotions at White & Case
13 October 2017 | New York | Reporter: Barney Dixon
White & Case has promoted 31 new partners, including four intellectual property attorneys, across the US and UK
Qualcomm hit with $775 million fine in Taiwan
13 October 2017 | Taipei | Reporter: Barney Dixon
Qualcomm has been hit with a $775 million fine, after the Taiwan Fair Trade Commission found that the chipmaker had abused its position in the baseband chip market
SUEPO willing to work with new EPO president
12 October 2017 | Munich | Reporter: Barney Dixon
A source close to the Staff Union of the European Patent Office has revealed it is always willing to work with whoever is elected to lead the European Patent Office
BPTO and EPO sign PPH cooperation treaty
12 October 2017 | São Paulo | Reporter: Barney Dixon
The Brazilian Patent and Trademark Office and the European Patent Office have signed a cooperation treaty, aimed at the creation of a patent prosecution highway between the two offices
Johnson Controls-Hitachi selects Anaqua
11 October 2017 | Boston | Reporter: Barney Dixon
The joint venture between Johnson Controls and Hitachi Air Conditioning has chosen intellectual property analytics company Anaqua to globalise its IP management systems